Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic or Locally Advanced Malignancies”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01443065
What this trial is testing

MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma

Who this might be right for
Malignant Neoplasm of EsophagusMalignant Neoplasm of Stomach
UNICANCER 162
Testing effectiveness (Phase 2)Study completedNCT00806156
What this trial is testing

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer

Who this might be right for
TumorOvarian Cancer
Nektar Therapeutics 178
Early research (Phase 1)Active Not RecruitingNCT06328439
What this trial is testing

Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd. 40
Large-scale testing (Phase 3)Ended earlyNCT02186301
What this trial is testing

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

Who this might be right for
Non-Small Cell Lung Cancer
Clovis Oncology, Inc. 100
Early research (Phase 1)Study completedNCT01032681
What this trial is testing

EMD 521873 in Advanced Solid Tumors, MTD Finding

Who this might be right for
Non-Hodgkin Lymphoma
Merck KGaA, Darmstadt, Germany 66
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229
What this trial is testing

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Who this might be right for
Carcinoma
AstraZeneca 367
Early research (Phase 1)Looking for participantsNCT06536400
What this trial is testing

Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

Who this might be right for
Solid Tumors
Haisco Pharmaceutical Group Co., Ltd. 316
Early research (Phase 1)Study completedNCT04468607
What this trial is testing

BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Genentech, Inc. 46
Early research (Phase 1)Ended earlyNCT02908451
What this trial is testing

AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer

Who this might be right for
Gastric CancerColorectal CancerPancreatic Cancer+1 more
AbGenomics B.V Taiwan Branch 39
Early research (Phase 1)Study completedNCT01068977
What this trial is testing

The Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Cancers
Genentech, Inc. 44
Large-scale testing (Phase 3)Study completedNCT00253422
What this trial is testing

Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors

Who this might be right for
Breast Cancer
Institute of Cancer Research, United Kingdom 698
Testing effectiveness (Phase 2)UnknownNCT05141747
What this trial is testing

MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Who this might be right for
Locally Advanced Gastric CancerMetastatic HER2 Positive Gastroesophageal Junction Cancer
Shanghai Miracogen Inc. 60
Testing effectiveness (Phase 2)Ended earlyNCT00923247
What this trial is testing

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Who this might be right for
Medullary Thyroid Carcinoma
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Looking for participantsNCT07488676
What this trial is testing

ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Who this might be right for
Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaPancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc. 150
Early research (Phase 1)UnknownNCT00682227
What this trial is testing

Peptide Vaccination in Treating Patients With Esophageal Cancer

Who this might be right for
Esophageal Cancer
University of Yamanashi 10
Early research (Phase 1)Study completedNCT01106508
What this trial is testing

A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsRecurrent or Refractory MedulloblastomaLocally Advanced or Metastatic Basal Cell Carcinoma
Novartis Pharmaceuticals 57
Early research (Phase 1)Study completedNCT02827968
What this trial is testing

Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumors
3D Medicines (Sichuan) Co., Ltd. 28
Early research (Phase 1)Looking for participantsNCT06418061
What this trial is testing

Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Who this might be right for
UnresectableLocally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd. 198
Testing effectiveness (Phase 2)Study completedNCT05661578
What this trial is testing

Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

Who this might be right for
PD-L1-selected Solid Tumors
Hoffmann-La Roche 64
Early research (Phase 1)Active Not RecruitingNCT05311397
What this trial is testing

A166 in Patients With Advanced Solid Malignant Tumors

Who this might be right for
Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 120
Next Page